Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.
Based on experience from the treatment of other autoimmune diseases and because of the limitations imposed by existing therapeutic options for Graves' disease (GD) and thyroid-associated ophthalmopathy (TAO), rituximab (RTX) was recently proposed as a novel therapy option. Here, we summarize the rationale for using RTX; give an overview of the possible mechanisms of action; and give an account of its effects and side-effects when used in GD and TAO. Scant evidence, originating from only a few methodologically inhomogeneous studies, suggests that RTX may prolong remission for hyperthyroidism over that seen with antithyroid drugs, at least in mild GD. Furthermore, in patients with TAO, who are unresponsive to conventional immunosuppressive therapy, RTX seems efficacious. As we wait for larger-scale randomized studies, RTX, should be considered experimental and reserved for patients who do not respond favourably to conventional therapy. It is the first in what is likely to be a series of new and emerging treatments specifically targeting relevant components of the immune system. Further studies will hopefully lead to improved and better tailored, individualized therapy for GD and especially TAO.
Hegedüs
Laszlo
L
Department of Endocrinology and Metabolism, Odense University Hospital, University of Southern Denmark, Denmark. laszlo.hegedus@ouh.regionsyddanmark.dk
Smith
Terry J
TJ
Douglas
Raymond S
RS
Nielsen
Claus H
CH
D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects*; D006111:Graves Disease / Q000188:drug therapy* / Q000276:immunology; D049970:Graves Ophthalmopathy / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use*; D008954:Models, Biological; D000069283:Rituximab
D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab
J Immunol. 2003 Jun 15;170(12):5897-911
12794116
Ann Rheum Dis. 2005 Jun;64(6):913-20
15550531
Ann Neurol. 2008 Aug;64(2):187-99
18655096
Blood. 2009 May 7;113(19):4521-4
19224759
Blood. 1994 Jan 15;83(2):435-45
7506951
Rheumatology (Oxford). 2008 Jun;47(6):821-7
18397955
Eur J Immunol. 2008 Jan;38(1):292-8
18085668
Eur J Endocrinol. 2006 Apr;154(4):501-10
16556711
Eur J Endocrinol. 2007 Jan;156(1):33-40
17218723
J Clin Endocrinol Metab. 2004 Oct;89(10):5076-80
15472208
Clin Exp Immunol. 2000 Jan;119(1):38-46
10606962
Eur J Immunol. 2001 Sep;31(9):2660-8
11536164
Clin Endocrinol (Oxf). 2005 Jan;62(1):24-9
15638866
Clin Endocrinol (Oxf). 2010 Jun;72(6):853-5
20039891
Immunol Rev. 2008 Aug;224:201-14
18759928
J Clin Endocrinol Metab. 2007 May;92(5):1769-72
17284622
N Engl J Med. 2008 Jun 12;358(24):2594-605
18550875
J Clin Endocrinol Metab. 2009 Aug;94(8):2708-16
19491222
J Immunol. 1999 Oct 15;163(8):4284-91
10510367
Am J Pathol. 2001 Sep;159(3):861-73
11549579
Clin Immunol. 2009 Oct;133(1):108-16
19632157
N Engl J Med. 2008 Feb 14;358(7):676-88
18272891
Inflamm Bowel Dis. 2007 Nov;13(11):1365-8
17604367
Rheumatology (Oxford). 2006 Nov;45(11):1432-6
16632482
J Exp Med. 1996 Nov 1;184(5):2049-53
8920894
J Immunol. 1998 Aug 1;161(3):1163-8
9686575
J Clin Endocrinol Metab. 2001 Feb;86(2):930-4
11158069
Acta Ophthalmol. 2009 Nov;87(8):927-9
19785644
Ann Oncol. 2003 Apr;14(4):520-35
12649096
Ophthalmology. 2010 Jan;117(1):133-139.e2
19818507
Clin Immunol. 2009 Mar;130(3):252-8
18964302
Endocrinol Metab Clin North Am. 2009 Jun;38(2):355-71, ix
19328416
Arthritis Rheum. 2006 Jul;54(7):2151
16802352
Arch Ophthalmol. 2009 Sep;127(9):1155-60
19752424
Clin Endocrinol (Oxf). 2010 Jun;72(6):729-30
20050856
J Exp Med. 2003 Feb 17;197(4):489-501
12591906
Arthritis Rheum. 2004 Nov;50(11):3580-90
15529346
N Engl J Med. 2009 Nov 26;361(22):2143-52
19940299
N Engl J Med. 2009 Mar 5;360(10):994-1001
19264688
Arthritis Rheum. 2004 Aug;50(8):2580-9
15334472
N Engl J Med. 2004 Jun 17;350(25):2572-81
15201414
N Engl J Med. 2000 Oct 26;343(17):1236-48
11071676
Eur J Endocrinol. 2008 Nov;159(5):609-15
18628345
Thyroid. 2006 Jul;16(7):709-10
16889501
Immunol Lett. 2003 Jul 3;88(1):85-6
12853167
Endocrinology. 2006 Oct;147(10):4559-60
16980441
Neurology. 1999 May 12;52(8):1701-4
10331706
Arthritis Rheum. 2007 Dec;56(12):3909-18
18050222
J Immunol. 1998 Oct 15;161(8):3912-8
9780157
J Immunol. 2001 Oct 15;167(8):4710-8
11591802
Immunol Lett. 2006 Mar 15;103(2):83-5
16280169
Gut. 2008 May;57(5):714-5
18408106
Eur J Endocrinol. 2006 Apr;154(4):511-7
16556712
Arthritis Rheum. 2006 Sep;54(9):2793-806
16947627
Ann Rheum Dis. 2002 Oct;61(10):883-8
12228157
Thyroid. 1991;1(2):129-35
1688014
Arthritis Rheum. 2006 May;54(5):1390-400
16649186
Arthritis Rheum. 2006 Nov;54(11):3612-22
17075806
Immunology. 1999 Jun;97(2):188-96
10447731
Eur J Immunol. 2004 Jan;34(1):263-72
14971052
Rheumatology (Oxford). 2001 Feb;40(2):205-11
11257159
Expert Opin Biol Ther. 2007 Jul;7(7):1061-78
17665994
J Clin Endocrinol Metab. 2007 Oct;92(10):3762-3
17933978
Clin Immunol. 2007 Jan;122(1):62-74
17046329
Nat Immunol. 2002 Oct;3(10):944-50
12244307
J Immunol. 2000 Aug 1;165(3):1626-33
10903773
Nature. 1985 Apr 11-17;314(6011):537-9
3157869
J Exp Med. 1989 Oct 1;170(4):1463-8
2677211
Ann Rheum Dis. 2007 Jun;66(6):818-20
17148544
J Clin Endocrinol Metab. 2007 May;92(5):1620-2
17483377
Thyroid. 2004 May;14(5):337-44
15186609